摘要
目的:评价滤过泡下注射bevacizumab(贝伐单抗,avastin)的临床效果和安全性。方法:回顾性分析一组滤过泡下注射bevacizumab1mg(0.04mL,25mg/mL)治疗滤过泡血管化的病例,患者均为复杂的小梁切除术后滤过泡血管化,经分离结膜下注射MMC而失败的病例8例8眼,bevacizumab注射后随访2～6mo。结果:注射后2wk眼压降低至正常占87.5%,滤过泡血管化消失占87.5%。所有患者均未出现高眼压、葡萄膜炎或其他眼内和全身不良反应。结论:滤过泡下注射bevacizumab治疗滤过泡血管化是一种较理想的选择,方法容易操作,并发症少,早期应用能获得更好的结果。但需进一步扩大样本多中心的临床随机对照研究。
AIM： To evaluate the safety and efficacy of sub-bleb bevacizumab injection in treatment of filtering bleb neovascularization. METHODS：A group of treament cases of filtering bleb by injecting bevacizumab 1 mg （0.04mL, 25mg/mL） were retrospectively analyzed. All the cases,8 cases of 8 eyes, were followed-up for 2-6 months. RESULTS： Two weeks after the injection, intraocular pressure dropped to normal in 87.5%, neovascularization of bleb disappeared in 87.5%. All the cases had not such symptoms as high intraocular pressure, uveitis, adverse reaction of inner eyes or the whole body. CONCLUSION ：The sub-bleb injection of bevacizumab is an ideal choice to inhibit the neovascularization. It is easy to operate with fewer complications. It can be more effective if used earlier. However, it still needs further large sample multicentre clinical research.
出处
《国际眼科杂志》
CAS
2010年第3期556-557,共2页
International Eye Science
